UM  > 中華醫藥研究院
Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy
Cai Y.1; Xu Y.1; Chan H.F.2; Fang X.1; He C.1; Chen M.1
2016
Source PublicationMolecular Pharmaceutics
ISSN15438384
Volume13Issue:3Pages:699
Abstract

Glycyrrhetinic acid (GA), the main hydrolysate of glycyrrhizic acid extracted from the root of licorice, has been used in hepatocellular carcinoma (HCC) therapy. Particularly, GA as a ligand in HCC therapy has been widely explored in different drug delivery systems, including liposomes, micelles, and nanoparticles. There is considerable interest worldwide with respect to the development of GA-modified drug delivery systems due to the extensive presence of GA receptors on the surface of hepatocyte. Up until now, much work has been focused on developing GA-modified drug delivery systems which bear good liver- or hepatocyte-targeted efficiency both in vitro and in vivo. Owing to its contribution in overcoming the limitations of low lipophilicity and poor bioavailability as well as its ability to promote receptor-mediated endocytosis, GA-modified drug delivery systems play an important role in enhancing liver-targeting efficacy and thus are focused on the treatment of HCC. Moreover, since GA-modified delivery systems present more favorable pharmacokinetic properties and hepatocyte-targeting effects, they may be a promising formulation for GA in the treatment of HCC. In this review, we will give an overview of GA-modified novel drug delivery systems, paying attention to their efficacy in treating HCC and discussing their mechanism and the treatment effects. © 2016 American Chemical Society.

KeywordAnti-hcc Delivery Systems Ga Liver-targeting
DOI10.1021/acs.molpharmaceut.5b00677
URLView the original
Language英语
WOS Research AreaResearch & Experimental Medicine ; Pharmacology & Pharmacy
WOS SubjectMedicine, Research & Experimental ; Pharmacology & Pharmacy
WOS IDWOS:000371753800001
The Source to ArticleScopus
Fulltext Access
Citation statistics
Cited Times [WOS]:36   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Corresponding AuthorChen M.
Affiliation1.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China
2.Department of Biomedical Engineering, Columbia University, New York 10027, United States
First Author AffilicationInstitute of Chinese Medical Sciences
Corresponding Author AffilicationInstitute of Chinese Medical Sciences
Recommended Citation
GB/T 7714
Cai Y.,Xu Y.,Chan H.F.,et al. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy[J]. Molecular Pharmaceutics,2016,13(3):699.
APA Cai Y.,Xu Y.,Chan H.F.,Fang X.,He C.,&Chen M..(2016).Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.Molecular Pharmaceutics,13(3),699.
MLA Cai Y.,et al."Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy".Molecular Pharmaceutics 13.3(2016):699.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Cai Y.]'s Articles
[Xu Y.]'s Articles
[Chan H.F.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Cai Y.]'s Articles
[Xu Y.]'s Articles
[Chan H.F.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Cai Y.]'s Articles
[Xu Y.]'s Articles
[Chan H.F.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.